AU2020414152B2 - Application of fusion protein in treating age-related macular degeneration - Google Patents

Application of fusion protein in treating age-related macular degeneration Download PDF

Info

Publication number
AU2020414152B2
AU2020414152B2 AU2020414152A AU2020414152A AU2020414152B2 AU 2020414152 B2 AU2020414152 B2 AU 2020414152B2 AU 2020414152 A AU2020414152 A AU 2020414152A AU 2020414152 A AU2020414152 A AU 2020414152A AU 2020414152 B2 AU2020414152 B2 AU 2020414152B2
Authority
AU
Australia
Prior art keywords
eye
ibi302
group
administration
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020414152A
Other languages
English (en)
Other versions
AU2020414152A1 (en
Inventor
Shujie Lu
Lei Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics (Suzhou) Co Ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of AU2020414152A1 publication Critical patent/AU2020414152A1/en
Application granted granted Critical
Publication of AU2020414152B2 publication Critical patent/AU2020414152B2/en
Priority to AU2025203373A priority Critical patent/AU2025203373A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2020414152A 2019-12-24 2020-12-23 Application of fusion protein in treating age-related macular degeneration Active AU2020414152B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203373A AU2025203373A1 (en) 2019-12-24 2025-05-09 Application Of Fusion Protein In Treating Age-Related Macular Degeneration

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911346311 2019-12-24
CN201911346311.2 2019-12-24
CN202011441025 2020-12-11
CN202011441025.7 2020-12-11
PCT/CN2020/138598 WO2021129658A1 (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203373A Division AU2025203373A1 (en) 2019-12-24 2025-05-09 Application Of Fusion Protein In Treating Age-Related Macular Degeneration

Publications (2)

Publication Number Publication Date
AU2020414152A1 AU2020414152A1 (en) 2022-08-04
AU2020414152B2 true AU2020414152B2 (en) 2025-02-13

Family

ID=76575187

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020414152A Active AU2020414152B2 (en) 2019-12-24 2020-12-23 Application of fusion protein in treating age-related macular degeneration
AU2025203373A Pending AU2025203373A1 (en) 2019-12-24 2025-05-09 Application Of Fusion Protein In Treating Age-Related Macular Degeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203373A Pending AU2025203373A1 (en) 2019-12-24 2025-05-09 Application Of Fusion Protein In Treating Age-Related Macular Degeneration

Country Status (8)

Country Link
US (1) US20230056821A1 (enExample)
EP (1) EP4082559A4 (enExample)
JP (2) JP2023509880A (enExample)
CN (2) CN118750581A (enExample)
AU (2) AU2020414152B2 (enExample)
CA (1) CA3165887A1 (enExample)
TW (2) TW202525865A (enExample)
WO (1) WO2021129658A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082563A1 (en) * 2011-12-01 2013-06-06 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
US10071136B2 (en) * 2014-09-25 2018-09-11 Innovent Biologics, Inc. Stable liquid formulations of recombinant fusion proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082563A1 (en) * 2011-12-01 2013-06-06 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
US10071136B2 (en) * 2014-09-25 2018-09-11 Innovent Biologics, Inc. Stable liquid formulations of recombinant fusion proteins

Also Published As

Publication number Publication date
WO2021129658A1 (zh) 2021-07-01
TWI879855B (zh) 2025-04-11
EP4082559A4 (en) 2024-01-03
EP4082559A1 (en) 2022-11-02
CN114867489A (zh) 2022-08-05
AU2025203373A1 (en) 2025-05-29
TW202525865A (zh) 2025-07-01
JP2024167222A (ja) 2024-12-03
TW202128746A (zh) 2021-08-01
AU2020414152A1 (en) 2022-08-04
JP2023509880A (ja) 2023-03-10
CA3165887A1 (en) 2021-07-01
CN118750581A (zh) 2024-10-11
US20230056821A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US20230056821A1 (en) Use of fusion protein in treatment of age-related macular degeneration
US20210205410A1 (en) Use of a vegf antagonist to treat angiogenic eye disorders
JP2021193115A (ja) 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
TWI581801B (zh) 治療血管新生相關之眼疾之組合物及方法
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
EP3278810A1 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CN109715189A (zh) 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
EA017945B1 (ru) Композиции и способы лечения и профилактики состояний фиброза, воспаления и неоваскуляризации глаза животного
US20160130321A1 (en) Use of a vegf antagonist in treating macular edema
KR20240161204A (ko) 안 질환의 치료 방법
WO2021048806A1 (en) Methods for treating ocular diseases
WO2019229116A1 (en) Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
US20230054032A1 (en) Compositions and methods for treating ocular disease
WO2025036488A1 (en) Methods of treating age-related macular degeneration and diabetic macular edema
CN106890313A (zh) 用于治疗病理性近视的药物
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases
Hakan et al. Evaluation Of The Effectiveness Of Intravitreal Anti-VEGF Injection With Intravitreal Dexamethasone Implant In Patients With Treatment-Resistant Diabetic Macular Edema
Komlos Association for Research in Vision and Ophthalmology (ARVO)-2022 Annual Meeting. Denver/Virtual-May 1-4 and 11-12, 2022
HK40094966A (en) Use of a vegf antagonist to treat diabetic retinopathy
JP2025517038A (ja) 黄斑浮腫又は網膜静脈閉塞の治療における使用のための単量体アネキシンａ５
HK40125761A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)